MYC-RIBOTAC

MYC-RIBOTAC

• UNSPSC Description: MYC-RIBOTAC is a nucleic acid-targeting degrader (ribonuclease-targeting chimera, RIBOTAC) that targets the MYC internal ribosome entry site (IRES). MYC-RIBOTAC contains a MYC mRNA binding component and a small molecule that recruits and locally activates RNAse L1. MYC-RIBOTAC reduces MYC mRNA and protein expression levels, induces cell apoptosis, and can be used for antitumor research[1]. MYC-RIBOTAC consists of pre-miR-155 binder Anticancer agent 167 (HY-156839), RNA binder NCI-B16 (HY-156215), and Linker Amino-PEG4-alcohol (HY-W008005).
• Target Antigen: Apoptosis; c-Myc; PROTACs
• Type: Reference compound
• Related Pathways: Apoptosis;PROTAC
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/myc-ribotac.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(NC1=CC(NC(NC2=CC=C(C3=NCCN3)C=C2)=O)=CC(C(NCCOCCOCCOCCOC4=C(O)C=C(/C=C5SC(NC6=CC=CC=C6)=C(C(OCC)=O)C\5=O)C=C4)=O)=C1)NC7=CC=C(C8=NCCN8)C=C7
• Molecular Weight: 1067.17
• References & Citations: [1]Tong Y, et.al. Programming inactive RNA-binding small molecules into bioactive degraders. Nature. 2023 Jun;618(7963):169-179.
• Shipping Conditions: Blue Ice
• Clinical Information: No Development Reported